Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi

MILWAUKEE, March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Provention Bio (Nasdaq: PRVB) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. 

Click here to learn how to join the action https://www.ademilaw.com/case/provention-bio-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Provention Bio's financial outlook and prospects are excellent and yet Provention Bio shareholders are expected to receive only $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction agreement unreasonably limits competing bids for Provention Bio by imposing a significant penalty if Provention Bio accepts a superior bid. Provention Bio insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Provention Bio's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Provention Bio.

If you own Provention Bio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/provention-bio-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                                       
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP